妇科恶性肿瘤紫杉醇化疗所致过敏反应诊治的中国专家共识(2023年版)  

China expert consensus on diagnosis and treatment of hypersensitivity reaction induced by paclitaxel chemotherapy for gynecological malignant tumors(2023 edition)

作　　者：中国抗癌协会妇科肿瘤专业委员会 中国医师协会微无创医学专业委员会妇科肿瘤学组 张师前[2] 王雅卓 The Chinese Gynecologic Cancer Society(CGCS)of China Anti-Cancer Association;The Gynecologic Oncology Group of Minimally-Invasive and Noninvasive Medicine Committee of the Chinese Medical Doctor Association

机构地区：[1]不详 [2]山东大学齐鲁医院 [3]河北省人民医院

出　　处：《肿瘤药学》2023年第6期693-701,共9页Anti-Tumor Pharmacy

摘　　要：紫杉醇类已广泛应用于妇科恶性肿瘤的化疗。过敏反应是紫杉醇化疗过程中的常见不良反应,严重者甚至会危及患者生命。预防紫杉醇过敏、及时诊断并给予规范治疗,对于提高妇科肿瘤治疗效果、降低患者死亡风险具有重要意义。本共识对紫杉醇化疗过敏反应的分级、诊断、治疗及预防等方面的内容进行了制定,旨在为妇科恶性肿瘤紫杉醇化疗所致过敏反应的规范化预防和诊治提供参考。Paclitaxel has been widely used in chemotherapy of gynecological malignant tumors.Hypersensitivity reac-tions to paclitaxel are common complications during its treatment,which can endanger the life of patients in severe cases.Therefore,prevention of paclitaxel-induced hypersensitivity reactions,timely diagnosis and standardized treatments are im-portant to improve the overall efficacy of paclitaxel antitumor therapy and to reduce the risk of mortality.This consensus has formulated the grading,diagnosis,treatment,and prevention of hypersensitivity reactions to paclitaxel chemotherapy,in order to provide reference for the standardized prevention and diagnosis and treatment of hypersensitivity reactions caused by paclitaxel chemotherapy for gynecological malignant tumors.

关 键 词：妇科肿瘤 紫杉醇 过敏反应 治疗 预防 专家共识 

分 类 号：R737.3[医药卫生—肿瘤]